Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TDR collaboration with the pharmaceutical industry.

W E Gutteridge1

  • 1win.gutteridge@btopenworld.com

Transactions of the Royal Society of Tropical Medicine and Hygiene
|May 30, 2006
PubMed
Summary

The Special Programme for Research and Training in Tropical Diseases (TDR) partnered with pharmaceutical companies to develop drugs for neglected tropical diseases. This collaboration successfully registered miltefosine for visceral leishmaniasis treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New tools for malaria therapy.

Parassitologia·2000
Same author

Designer drugs: pipe-dreams or realities?

Parasitology·1997
Same author

Nitric oxide synthase activity in malaria-infected mice.

Parasite immunology·1996
Same author

Characterization of the enhanced transport of L- and D-lactate into human red blood cells infected with Plasmodium falciparum suggests the presence of a novel saturable lactate proton cotransporter.

The Journal of biological chemistry·1995
Same author

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.

Experimental parasitology·1995
Same author

The activity of hydroxynaphthoquinones against Leishmania donovani.

The Journal of antimicrobial chemotherapy·1992

Area of Science:

  • Tropical disease research
  • Pharmaceutical industry collaboration
  • Drug development

Background:

  • The Special Programme for Research and Training in Tropical Diseases (TDR) was established in 1976.
  • The pharmaceutical industry began reducing investment in tropical disease drug discovery around the same time.
  • TDR's initial goal was to prevent the discontinuation of promising drug candidates.

Purpose of the Study:

  • To explore alternative collaboration models with the pharmaceutical industry.
  • To identify and develop drugs for tropical diseases from existing industry pipelines.
  • To secure the registration and availability of miltefosine for visceral leishmaniasis.

Main Methods:

  • Collaborated with pharmaceutical companies to repurpose drugs developed for other indications.

Related Experiment Videos

  • Initiated a joint development project for an oral formulation of miltefosine with Asta Medica (later Zentaris).
  • Navigated challenges during the drug development process.

    • Main Results:

    • Miltefosine, initially developed as an antitumour agent, was successfully repurposed for visceral leishmaniasis.
    • Miltefosine received registration for visceral leishmaniasis treatment in India, Germany, and Colombia.
    • The successful collaboration served as a model for new Public Private Partnerships.

    Conclusions:

    • TDR's strategic collaborations with the pharmaceutical industry are crucial for developing treatments for tropical diseases.
    • Repurposing existing drug candidates can be an effective strategy for neglected diseases.
    • Successful public-private partnerships, like those spawned by TDR, are vital for global health initiatives.